From July 1, 2021 to September 30, 2021, the company has repurchased 3,293,161 shares, representing 1.27% for $642.2 million. With this, the company has completed the repurchase of 3,293,161 shares, representing 1.27% for $642.2 million under the buyback announced on June 24, 2021.
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
395.2 USD | +0.44% | -0.26% | -2.80% |
Apr. 18 | Vertex Pharmaceuticals Says FDA Granted Rolling Review of Suzetrigine to Treat Acute Pain | MT |
Apr. 17 | UBS Adjusts Vertex Pharmaceuticals Price Target to $466 From $498, Maintains Buy Rating | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-2.80% | 102B | |
+1.83% | 96.07B | |
-1.80% | 21.66B | |
-17.67% | 20.77B | |
-6.91% | 18.53B | |
-42.00% | 16.91B | |
-27.98% | 13.79B | |
-0.20% | 13.33B | |
+19.30% | 10.94B | |
-23.17% | 8.57B |
- Stock Market
- Equities
- VRTX Stock
- News Vertex Pharmaceuticals Incorporated
- Tranche Update on Vertex Pharmaceuticals Incorporated's Equity Buyback Plan announced on June 24, 2021.